Adult stem cell products could be lining up to penetrate the inflammation and orthopedics markets, judging by the recent $1.38 billion paid by Genzyme for Osiris's mesenchymal stem cell technology.

The company remains convinced of the product's merits and—bolstered by the backing of a $1.38 billion deal from Genzyme a year ago—continues to pursue cardiac and other autoimmune indications.

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling. Net sales were €8,391 million ...

Marc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for the company’s Genzyme unit. A pharmaceutical physician with experience in R&D, global medical affairs ...